

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AP2/22 - Antithrombotic Agents

Deadline: 16.09.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban														
— Samples and groups	[µg/L]				31							31	30	97%
Sample A1		74,5	9,3	13	31	CVP	74,5	4,1	25%	55,8	93,2	31	30	97%
(2) Chromogenous substrat		74,5	9,3	13	31	0						31		
Sample B1		294	21	7,2	31	CVP	294	9,3	25%	220	368	31	31	100%
(2) Chromogenous substrat		294	21	7,2	31	0						31		
Set 2														
(109) Dabigatran														
— Samples and groups	[µg/L]				34							34	30	88%
Sample A2		44,8	5,4	12	34	CVP	44,8	2,3	25%	33,6	56	34	30	88%
(1) Coagulometer		45,9	4,0	8,6	24	0						24		
(2) Chromogenous substrat		42,1	6,5	16	10	0						10		
Sample B2		223	22	10	34	CVP	223	9,4	25%	167	279	34	33	97%
(1) Coagulometer		228	27	12	24	0						24		
(2) Chromogenous substrat		214	9,8	4,6	10	0						10		
Set 3														
(110) Rivaroxaban														
— Samples and groups	[µg/L]				38							38	37	97%
Sample A3		73,0	6,3	8,6	38	CVP	73	2,5	25%	54,7	91,3	38	37	97%
(2) Chromogenous substrat		73,0	6,3	8,6	38	0						38		
Sample B3		299	28	9,4	38	CVP	299	11	25%	224	374	38	38	100%
(2) Chromogenous substrat		299	28	9,4	38	0						38		

st_kn_p

End of report

Printed: 21.09.2022